AAMU
AERI

Amundi Asset Management US’s Aerie Pharmaceuticals AERI Stock Holding History

Amundi Asset Management US’s Portfolio AERI Stock Details AERI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-2,900
Closed -$86K – 1731
2019
Q2 		$86K Hold
2,900
– – ﹤0.01% 1582
2019
Q1 		$138K Hold
2,900
– – ﹤0.01% 1506
2018
Q4 		$105 Buy
+2,900
New +$136K ﹤0.01% 1500

Other funds holding AERI

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

Amundi Asset Management US's AERI Position: Q3 2019 in Review

Amundi Asset Management US sold out of Aerie Pharmaceuticals (AERI) in Q3 2019, closing a stake of 2,900 shares — an estimated $86K sold.

Amundi Asset Management US first reported a position in AERI in Q4 2018 and held it in 3 quarters. The position peaked at $138K in Q1 2019. 167 funds tracked by Wall St. Rank hold AERI as of Q3 2019.

  • Amundi Asset Management US reported no remaining Aerie Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Amundi Asset Management US sold 2,900 Aerie Pharmaceuticals shares in Q3 2019, an estimated $86K.
  • Amundi Asset Management US first reported a position in Aerie Pharmaceuticals in Q4 2018 and held it in 3 quarters.
  • Amundi Asset Management US's Aerie Pharmaceuticals position peaked at $138K in Q1 2019.
  • 167 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q3 2019.

Based on Amundi Asset Management US's 13F filing for Q3 2019, filed 14 Nov 2019.